

Brigham and Women's Hospital
 Founding Member, Mass General Brigham

HARVARD
 MEDICAL SCHOOL

Optimizing Osteoporosis Prevention and Treatment: The Bone Health and Osteoporosis Foundation's Clinician's Guide 2022

Meryl S. LeBoff, MD
 Chief, Calcium and Bone Section, Brigham and Women's Hospital
 Endocrinology, Diabetes and Hypertension Division
 Professor of Medicine, Harvard Medical School

Larry Raisz Plenary Lecture
 May 5, 2022

1

Lawrence G. Raisz, M.D. Memorial Lecture Award



2

Disclosures

- Stock ownership Johnson & Johnson; Amgen
- Research Funding: Grants R01 AR070854, R01 AR060574, R01 AR059775 (PI, M.S. LeBoff) from National Institute of Arthritis Musculoskeletal and Skin Diseases and R01 AG071611 (PI, M.S. LeBoff and C. Crandall) from the National Institute of Aging

3

CONDENSING STATEMENT

The clinician's guide to prevention and treatment of osteoporosis

M.S. LeBoff¹, S.L. Greenspan², K.L. Insogna³, E.M. Lewicki⁴, K.G. Saag⁵, A.J. Singer⁶, E.S. Sims⁷

Published September 2021 / Updated 19 February 2022

© The Author(s)

Abstract
 Osteoporosis is the most common metabolic bone disease in the USA and the world. It is a subclinical condition and complicated by fractures. These fractures place an excessive medical and personal burden on individuals who suffer from them and take a significant economic toll. Any new fracture in an adult aged 50 years or older signifies a major elevated risk for subsequent fractures, particularly in the year following the initial fracture. What a patient experiences in a fall-related accident may be seen as a sentinel event indicative of bone fragility and increased future fracture risk even without the result of considerable trauma (Lurie et al. *Compendium* 1(14): 1010-1017, 2005; Mooney et al. *JAMA* 298(20): 2497-2506, 2007). Clinical or subclinical vertebral fractures, the most common type of osteoporotic fractures, are associated with a 5-fold increased risk for additional vertebral fractures and a 2- to 3-fold increased risk for fractures at other sites. Untreated osteoporosis can lead to a vicious cycle of recurrent fractures, often resulting in disability and premature death. In appropriate patients, treatment with effective antifracture medication prevents fractures and improves outcomes. Primary care physicians and medical specialists are critical gatekeepers who can identify fractures and initiate prevent osteoporosis interventions (osteoporosis detection, diagnosis, and treatment should be routine practice in all adult healthcare settings). The National Osteoporosis Foundation (NOF) first published the Clinician's Guide in 1999 to provide accurate information on osteoporosis prevention and treatment. Since that time, significant improvements have been made in diagnostic technologies and treatments for osteoporosis. Despite these advances, a daunting gap persists in patient care. As risk patients are often neglected to establish fracture probability and are educated about fracture prevention. More concerning, the majority of high-risk women and men who have a fracture are not diagnosed and do not receive effective, FDA-approved therapies. These overlooked opportunities are outlined to take the resolution as prescribed. The Clinician's Guide offers evidence-based recommendations regarding prevention, risk assessment, diagnosis, and treatment of osteoporosis in postmenopausal women and men aged 50 years and older. It includes indications for bone densitometry as well as fracture risk thresholds for pharmacologic intervention. Current medications build bone and/or decrease bone breakdown and dissimilation (reduce fracture fractures). All antifracture therapies tend to do so to ease the disease. Skeletal architecture remains superior at 180° when a medication is discontinued—marker for non-biphosphonates and later for biphosphonates. Even if a patient has a subclinical osteoporosis and elevated risk for fracture are still present (Lewicki et al.

4

Bone Health and Osteoporosis Foundation (BHOFF) Clinician's Guide:
Comprehensive Review of All Aspects of the Care of Patients with Low Bone
Mass and Osteoporosis

- Osteoporosis Impact and review
- How to diagnose low bone mass and osteoporosis
- Treatment considerations and new therapeutic approaches
- Rehabilitation and pain management following fragility fractures
- Importance of Secondary Fracture Prevention



5

5

Osteoporosis is a Prevalent Disease



- **1 out of 2 women and 1 out of 5 men** ≥ 50 years will suffer an osteoporotic fracture
- **2 million fractures** each year in U.S.... **projected to increase to 3.2 million in 2040**
- Fractures result in >432,000 hospital admissions, ~2.5 million office visits, and ~180,000 nursing home admissions
- Costs are expected to increase from \$57 billion to over \$95 billion by 2040
- This heavy personal and economic toll could be reduced by routine evaluation and treatment

Lewicki EM et al. JBMR 2019
Burge R et al. JBMR 2007




6

6

What is Osteoporosis?

Low bone mass and
microarchitectural changes
that lead to reduced bone
strength and increased
fractures




Dempster DW, et al. J Bone Miner Res. 2000
NIH Consensus Development Panel. JAMA. 2002
Lukuff MS, Greenspan SL, Hasegawa H, et al. Osteo Int. In Press. 2012



7

7

Bone is a Dynamic Organ: Osteoporosis Results from a Net
Increase in Bone Breakdown Relative to Bone Formation




Raisz, LG. The Journal of Clinical Investigation, 2005



8


8

A Fracture is A Sign of Osteoporosis



9

Vertebral Fractures: Only 1/3 are Clinically Diagnosed




- Patients with spine fractures have a 5-fold increased risk of another spine and 2-fold risk of a hip fracture
- Predict future fractures *independent* of BMD
- Associated with increased morbidity and mortality
- Importance of spine imaging

Blicic et al. JAMA, 2009
Roux et al. Ann Intern Med. 1991
Cooper et al. Bone, 1993

10

A Spot Light on Wrist Fractures



- Most common fracture of the upper extremity and five times greater risk in women than men
- Early fracture with increased incidence with age
- In **women** and **men** recent data show that a wrist fracture is associated with *an increased risk* of other fragility fractures

Crandall CJ, Hoey KM, Cauley JA, LeBoff MS. JBMR. 2015
Crandall CJ, Hoey KM, Brennan-Cox, ... LeBoff MS. JGIM. 2015
Sims, E.S., et al. Osteoporos Int. 2014
Edwards, R. et al. BMC. 2012
Burge R et al. J Bone Min Res. 2007
Lewin, N. et al. Osteoporos Int. 2014
Wright, N., Hosker, C., Nelson, Osteoporos Int. 2018

11

Associations Between Incident **Wrist Fracture** (n=8,792) and **Subsequent Fracture(s)**: Hazard Ratios


Fracture	Event	Hazard Ratio	95%CI
Any Non-Wrist	33,596	1.40	1.33-1.48
Spine	5,301	1.48	1.32-1.66
Humerus	4,309	1.78	1.57-2.02
Upper Extremity	7,228	1.88	1.70-2.07
Lower Extremity	14,867	1.36	1.26-1.48
Hip	3,801	1.50	1.32-1.71

Model: Adjusted for age, race and BMI

Crandall CJ, Hoey KM, Cauley JA et al. LeBoff, MS. JBMR 2015

12


Hip Fractures: The Most serious Fractures



Leibson CL, et al. *Journal of the American Geriatric Society*. 2002
 Magaziner, et al. *American Journal of Epidemiology*. 2003
 Cooper C, et al. *BMJ*. 1997
 National Osteoporosis Foundation

13

Decline in Hip Fractures Has Plateaued: Only 35% to 40% Medicare patients with fractures are evaluated and treated for their underlying osteoporosis



14
 Lewicki EM, et al. *Osteoporosis Int*. 2018
 NIOSA, HEDIS Measures and Technical Resources <https://www.cms.gov/medicare/quality/niosa>, 2020

14


Diagnostic considerations



15

Why is Important to Diagnose Secondary Causes of Osteoporosis?

- Reduced acquisition of peak bone mass, a determinant of osteoporosis later in life
- Increased bone loss and elevated fracture risk
- Skeletal changes that may be reversible



16

16

Risk Factors: Medical Disorders

Gastrointestinal disorders:

- Celiac disease
- Inflammatory bowel disease
- Pancreatic disease
- Primary biliary cirrhosis
- Gastric bypass

Hematologic disorders:

- Multiple myeloma
- Sickle cell disease
- Leukemia/lymphoma
- Systemic mastocytosis

Rheumatologic diseases

- Rheumatoid arthritis
- Systemic lupus
- Ankylosing spondylitis

Genetic diseases


- Cystic fibrosis
- Ehlers-Danlos
- Hemochromatosis
- Hypophosphatasia
- Marfan syndrome
- Osteogenesis imperfecta

Neurologic disorders:

- Epilepsy
- Multiple sclerosis
- Parkinson's disease
- Spinal cord injury
- Muscular dystrophy
- Stroke

Misc:

- Acquired Immune Deficiency Syndrome
- Chronic Obstructive Pulmonary Disease
- End-Stage Renal Failure
- Post-transplant bone disease
- Hypercalcaemia and nephrolithiasis
- Congestive Heart Failure



Urticaria Pigmentosa

Leiboff MS, Greenspan SL, Insogna KL, et al. Osteo Int. In Press 2022 17


17

Risk Factors: Medications

Medications:

- **Glucocorticoids**
- Thyroid hormone (excess)
- Depo-medroxyprogesterone
- Tamoxifen (premenopausal use)
- Aromatase inhibitors
- Androgen suppression
- GnRH agonists
- Proton pump inhibitors

- Selective serotonin reuptake inhibitors
- Thiazolidinediones
- Lithium
- Methotrexate
- Cyclosporine A & tacrolimus
- Chemotherapy agents
- Anticoagulants (heparin)
- Anticonvulsants (e.g. phenobarbital, phenytoin, valproate)





Leiboff MS, Greenspan SL, Insogna KL, et al. Osteo Int. In Press 2022 18

18

How Do You Evaluate a Patient with Osteoporosis?

- Detailed history, calculated calcium intake, and physical examination
- Family History
- Falls History
- Height Measurement (with stadiometer)
- Bone Density testing
- Laboratory Tests






19

19

Dual-energy X-ray Absorptiometry (DXA)

- Measures areal BMD (aBMD) spine, hip, forearm and VFA
- Low radiation
- Utility of DXA
 - Diagnose osteoporosis and monitor treatment
 - Predict fracture risk

FNH Bone Quality Study: Meta-regression Analysis showed larger Improvements in BMD associated with greater reductions in fracture risk (e.g., 4% increase in lumbar spine BMD associated with 62% decrease in vertebral fracture and a 38% reduction in hip fracture)



Vertebral Fracture Assessment

Bouillon ML, et al. JBMR 2019

20

20

How are Low Bone Mass and Osteoporosis Diagnosed?

World Health Organization Criteria	
Category	T-Score
Normal	-1.0 or above
Low Bone Mass (Osteopenia)	-1.1 to -2.4
Osteoporosis	-2.5 or below



21

21

Who Should Have A Bone Density Test?

- Postmenopausal women and men ≥ 50 with **>1 risk factor****
- **Women: \geq Age 65 yrs***
- **Men: \geq Age 70 yrs***
- Fracture ≥ 50 years
- Vertebral Deformity
- Hyperparathyroidism
- Glucocorticoid therapy (≥ 5.0 mg/d ≥ 3 months)
- Monitor response to therapy
- Medical necessity

Medicare Mandate 1998
 *Lofoff MS, Greenquist SL, Insogna KL, et al. *Osteo Int.* In Press 2022
 **Watts N, et al. *JGIM* 2012
 US Preventive Services Task Force JAMA 2018



22

22

Consider Bone Density Test at the 33% Radius in the Following Patients

- BMD cannot be measured at the spine or hip (e.g, bilateral hip replacements or obesity)
- Hyperparathyroidism
- Hyperthyroidism
- Androgen deprivation therapy for prostate cancer (metastatic disease)
- Those undergoing Orthopedic Surgery



Lofoff MS, Greenquist SL, Insogna KL, et al. *Osteo Int.* In Press 2022 23

23

Risk Factors and Bone Density: FRAX®

Country: **USA (United States)** Name: Patient 1 About this tool factors ⓘ

Questionnaire:

1. Age (Default: 65 for women or 70 for men) 10. Sex (Default: osteoporosis) 20. Fracture (Check BMD)

2. Sex 3. Weight 4. Height 5. Previous fracture 6. Parent/child hip 7. Current smoking 8. Glucocorticoids 9. Rheumatoid arthritis

10-year probability of fracture:

- Major osteoporosis: 28.4%
- Hip fracture: 19%

*Indicated for those with BMD in low bone mass (osteopenia range)

- Postmenopausal women and men age ≥ 50

*Treatment thresholds in U.S.:


- 10-year probability of hip fracture $\geq 3\%$
- 10-year probability of major osteoporosis-related fracture $\geq 20\%$



www.ihf.ac.uk/FRAX 24

24

Hip BMD showing Low Bone Mass and a History of Fracture: FRAX® score indicates an elevated absolute risk



Sex: Female Height: 64.5 in
Ethnicity: White Weight: 115.0 lb
Age: 61

Region	Areal (cm ²)	BMC (g)	BMD (g/cm ³)	T-score	PRE(%)	Z-score	AM(%)
Neck	5.14	3.34	0.649	-1.8	76	-0.5	93
Troch	11.79	6.68	0.567	-1.4	81	-0.4	93
Infer	11.92	15.03	0.819	-1.7	76	-0.9	85
Total	34.85	25.04	0.719	-1.8	76	-0.8	88
Ward's	1.14	0.56	0.493	-2.1	67	0.0	100

Total BMD CV 1.0%
WHO Classification: Osteopenia

10 year Fracture Risk	Without Prior Fracture	With Prior Fracture
Major Osteoporotic Fracture	19%	30%
No Fracture	2.2%	4.2%


Reported Risk Factors: US (Caucasian), Neck BMD = 0.649, BMI = 18.4, Past/Fracture, smoking (rheumatoid arthritis)

FRAX® version 3.0. Fracture probability calculated for an untreated patient. Fracture probability may be lower if the patient has received treatment.

Kanis JA, et al. *Osteo Int.* 2011

25

Who Should Have a Vertebral Imaging/Vertebral Fracture Assessment (VFA)?



Measured height loss

- Historical height loss of ≥ 1.5 inches
- Prospective height loss of ≥ 0.8 inches

In all women ≥ 70 yrs. and all men ≥ 80 yrs. if T-score is ≤ -1.0

In women aged 65-69 yrs. and men aged 75-79 yrs. if T-score is ≤ -1.5

Postmenopausal women and men ≥ 50 yrs. with Risk Factors:


- Fractures
- Glucocorticoids
- Hyperparathyroidism

International Society for Clinical Densitometry (ISCD) Official Positions – Adult 2019
Lukoff MS, Greenspan SL, Brogna KL, et al. *Osteo Int.* In Press 2022

26

Trabecular Bone Score (TBS) in Patients with Low Bone Mass

- Textural measure of spine DXA images to estimate structural characteristics
- Predicts fracture risk independent of BMD and FRAX®
- Higher TBS associated with better bone microarchitecture
- TBS-adjusted FRAX



BMD = 0.972 TBS = 1.459
BMD = 0.969 TBS = 1.243

Harris D, et al. *Journal of Clinical Densitometry* 2011
Roux JP, et al. *Osteoporosis Int.* 2013
Siva BC, et al. *J Bone Miner Res.* 2013
Kraig MA, et al. *Osteoporosis* 2014
Goldstein AM, et al. *Osteoporosis Int.* 2018


27

Other Imaging Technologies: Used in Research

DXA for Body Composition: aBMD (whole body) and body composition (total and regional fat and lean tissue and VAT)

Peripheral Quantitative Computed Tomography (pQCT) at Radius and Tibia: Total, trabecular, and cortical volumetric (v)BMD and strength indices at the radius and tibia

High-Resolution Peripheral Quantitative Computed Tomography (HR-pQCT) at Radius and Tibia: Microarchitecture, cortical and trabecular bone vBMD, trabecular number, thickness, and separation and strength indices



28

Other Imaging Technologies (Cont)

Computed Tomography (QCT): vBMD of the spine or proximal femur using calibration approaches. Finite Element Analyses provide estimates of bone strength. Higher radiation exposure than DXA. Opportunistic QCT uses tests performed for other reasons with a synchronous calibration to assess vBMD

Magnetic Resonance Imaging (MRI): MRI imaging to estimate bone geometry and trabecular bone structure of the radius, tibia, femur and calcaneus. No ionizing radiation



29

29

Universal bone health recommendations



30

Universal Recommendations

- Recommend daily calcium (ideally from diet)
- Vitamin D 800-1000 IU/daily
- Counsel on fall prevention
- Advocate regular weight-bearing exercises
- Advocate smoking cessation and limited alcohol intake



31

31

Estimate Dietary Calcium Intake from Calcium-Rich foods

Product	# of Servings/d	Estimated calcium/ serving, in mg	Calcium in mg
Milk (8 oz.)	_____	X 300	= _____
Almond/soy milk (8 oz.)	_____	X450	= _____
Yogurt (6 oz.)	_____	X 300	= _____
Cheese (1 oz. or 1 cubic in.)	_____	X 200	= _____
Fortified foods or juices	_____	X 80 to 1,000**	= _____
Tofu, firm (8 oz.)	_____	X 250	= _____
		Subtotal	= _____
STEP 2: Add 250 mg for non-dairy sources to subtotal			+ 250
TOTAL Calcium, in mg			= _____



*About 75 to 80% of the calcium consumed in American diets is from dairy products

**Calcium content of fortified foods varies, and it is important to review individual labels

LeBoff MS, Greenspan SL, Insogna KL, et al. Osteo Int. 2022 32

32

Recommended Calcium and Vitamin D Intakes for Women and Men				
LIFE STAGE GROUP	CALCIUM IOM/BHOF (mg/day)	CALCIUM Safe upper limit (mg/day)	VITAMIN D IOM/BHOF (units/day)	VITAMIN D Safe upper limit (units/day)
51+ year old women	1,200	2500	600/800-1000	4000
51-70-year-old men	1,000	2000	600/800-1000	4000
71+ years old men and women	1,200	2000	800/800-1000	4000

LeBoff MS, Greenspan SL, Insogna VL, et al. *Osteo Int.* 2022
 Ross AC, Manson JE, Abrams DA, et al. *AZIM.* 2011

33

How Much Vitamin D For Bone?

- Deficiency: < 20 ng/ml
- **Goal for 25(OH)D level: ≥ 30 ng/ml**
- Reference Range 20-50 ng/ml


34

Large Population-Based, Primary Prevention Study in Generally Healthy Adults: VITamin D and Omega-3 TrialL (VITAL)

- VITAL is a research study in 25,874 men and women enrolled from 50 states that investigated whether daily supplemental vitamin D₃ (2000 IU) and/or omega-3 fatty acids (fish oil; 1g) reduced the risk of cancer, heart disease, and stroke.
- VITAL Effects of vitamin D and/or fish oil on fractures and bone health measures (R01 AR 60574 and R01 AR 059775 PI: MS LeBoff)

BWH Division of Preventive Medicine and Endocrinology, Diabetes and Hypertension

35



36


How much Exercise for Adults with Low Bone Mass and Osteoporosis? BHOE Guide

- Weight-bearing activities**
 - 30 min on most days of the week in a single 30-min session or in multiple sessions spread throughout the day
- Muscle strengthening activities**
 - 2-3 days per week. Can be done all at once or in multiple short sessions, full body or one body part per day (for example, arms one day, legs the next and trunk the next)
- Balance, posture, and functional activities**
 - Every day or as often as needed. Focus on area of most need: If patient has fallen, balance activities should be emphasized. If patient has trouble climbing stairs or getting up from the couch, he/she should do more functional exercises

Libuff MS, Greenman SL, Inagiri KL, et al. *Osteo Int*. In Press. 2022
 BHOE Health Professional's Guide to Rehabilitation of the Patient with Osteoporosis, 2003
 BHOE Boring up on osteoporosis, 2019

37

Activities that Require Spinal Flexion Increase Risk of Spine Fractures and Spinal Extension Exercises Decrease Risk



Sinaki M, Mikellin BA. *Arch Phys Med Rehabil*. 1984

38

US FDA-Approved Drugs for Osteoporosis



FDA-Approved Drug Therapies on Fracture Reductions

	Vertebral fracture	Hip fracture	Non-spine
Alendronate	X	X	X
Risedronate	X	X	X
Ibandronate	X	No	No
Zoledronic acid	X	X	X
Hormone therapy (prevention)	X	X	X
Raloxifene	X	No	No
Denosumab	X	X	X
Teriparatide	X	N/A	X
Abaloparatide	X	N/A	X
Romosozumab	X	Post ALN	X

40

39

40

Consider osteoporosis treatment in postmenopausal women and men ≥ 50 yrs. for:

Primary Fracture Prevention:

- T-Score ≤ -2.5 at femoral neck, total hip, lumbar spine, 33% radius
- Low bone mass (osteopenia: T-score between -1.0 and -2.5) by DXA with FRAX score and 10-year hip fracture risk $\geq 3\%$ or a 10-year major osteoporosis-related fracture risk $\geq 20\%$

Secondary Fracture Prevention:

- Fracture of the hip or vertebra regardless of BMD
- Fracture of distal forearm, proximal humerus, or pelvis in persons with low bone mass



LeBoff MS, Greenspan SL, Insogna KL et al. *Osteo Intern* 2022 in Press 41

41

Inhibitors of Bone Breakdown: Bisphosphonates


- **Oral bisphosphonates:** alendronate, risedronate given once weekly
 - FDA approved for Prevention and Treatment of Osteoporosis and other indications
- **Intravenous bisphosphonate:** Zoledronic Acid given once a year.
 - Approved with post-hip fracture with vitamin D
 - In women aged ≥ 65 years with low hip BMD, zoledronic acid administered every 18 months for 6 years reduced vertebral and nonvertebral fractures
- Rare risk of osteonecrosis of the jaw and atypical femur fractures and flu-like symptoms with zoledronic acid
- Meta-analysis of RCTs found *no delay* in fracture healing with bisphosphonates



Xue Q, et al. *J Orthop Surg Res*. 2014 41

42

Zoledronate and Vitamin D Post-hip Fracture: Reduced Clinical, Spine, and Non-spine Fractures




Lyles et al. *N Engl J Med* 2007 43

43

Other Inhibitors of Bone Breakdown: Denosumab

- Denosumab is a fully human monoclonal antibody against RANKL
- Administered as a SQ injection every 6 months
- Rare skin and other infections, rare risk of osteonecrosis of the jaw and atypical femur fractures
- If not given every 6 months rebound bone breakdown and spine fractures. When stopping start another antiresorptive medication

Effects of 3 Years of Denosumab on Spine BMD




Cummings S et al. *N Engl J Med* 2009 44

44

Stimulators of Bone Formation

- Teriparatide (PTH1-34) or **Abaloparatide (PTHrP 1-34)**
- Administered as a daily SQ injection (abaloparatide injected peri-umbilically)
- Optimally started before an inhibitor of bone breakdown
- Follow treatment with an antiresorptive agent, usually a bisphosphonate or denosumab, to maintain or further increase BMD

Effect of rhPTH[1-34] on the Risk of New Vertebral Fractures




45

Who is a candidate for Teriparatide (1-34 PTH) or Abaloparatide (PTHrP 1-34).

- Adult-motivated to take daily injection
- Women and men at high risk for fractures
- Do not use in patients with: hypercalcemia, XRT, skeletal malignancy, elevated alkaline phosphatase, Paget's Disease,
- BLACK BOX warning concerning osteosarcoma risk in rodents recently removed for both
- Teriparatide but not abaloparatide is currently approved for use beyond 2 years

Effect of Abaloparatide and Teriparatide on Fracture Risk




Miller PD, et al. JAMA 2016
McCloskey KV, et al. Arch Osteo. 2019

46

Romozosumab: Anabolic Therapy

- A fully human monoclonal antibody to sclerostin
- FDA-approved for treatment of osteoporosis in postmenopausal women at high risk for fracture
- Administered as monthly injections for 1 year
- Black Box warning - Major cardiac events: should not be initiated if had a myocardial infarction or stroke within preceding year
- Follow-up therapy with denosumab and, to a lesser degree, alendronate preserve or continue to accrue BMD benefits



Lewicki EM. JBMR 2018
Coulton F, et al. JBMR 2018
McClung MR, et al. JBMR 2018
Saag KG, et al. NEJM 2017

47

Osteoporosis Treatments are Effective

	VERTEBRAL FRACTURE	HIP FRACTURE
Inhibitors of Bone Breakdown		
Alendronate	↓44%	↓53%
Zoledronate	↓70%	↓41%
Denosumab	↓68%	↓40%
Stimulators of Bone Formation		
Teriparatide	↓65%	Not assessed. (Non-Vert Fractures by 53%)
Abaloparatide	↓86%	Not assessed. (Non-Vert Fractures by 43%)
Romozosumab	↓73%	No. ↓38%* (ROMO followed by ALN vs ALN followed by ALN)

Cummings, et al. JBMR 1998
Black, et al. AZM 2000
Black, et al. NEJM 2007
Cummings, et al. NEJM 2009
Nieves PMA, et al. Engl J Med 2001
Miller, et al. JAMA 2016
Coulton F, et al. JBMR 2018
Saag KG, et al. NEJM 2017

48

What Medications Reduce Wrist Fractures?

- Alendronate- in women with low bone mass and an existing vertebral fracture (HR=0.52; p=0.013)
- Zoledronic Acid- in older women with osteopenia [HR=0.56 (0.37-0.85)]
- Denosumab- in patients with T-score ≤ -2.5 (40% absolute risk reduction p=0.03)
- Estrogen and Progesterone-women enrolled in WHI [HR=0.71(0.69-0.85)]
- Abaloparatide- HR=0.77; p = 0.051, trend was greater than teriparatide



Black D, M., Cummings S, R., Karst D, B, et al. The Lancet 1996
 Reid I, R., Horow, A.M., Mihov, B, et al. NEJM 2018
 Siris S.A., Richman C., Morini J, A.H, et al. Menopause 2013
 Watts NB, Dove RK, Bain S ... LeBoff MS, Orwoll ES 2021
 Cauley JA, Robbins J, Chen Z, Cummings SR ... LeBoff MS et al. JAMA. 2003

49



Treatment considerations: Pharmacologic Therapies



50

Importance of Sequence of Therapies: Anabolic followed by Anti-resorptive

DATA-Switch Study Design



Leder BZ, Tsai JN, Likhim AV et al. Lancet 2015 51

51

Who Should have a Drug Holiday? ASBMR Task Force


SUMMARY

Treatment duration: 5 years on oral (alendronate) or 3 years on intravenous (zoledronic acid). Then reassess fracture risk and consider *drug holiday* and reevaluate in 2 to 3 years

Those who remain at **high risk** should continue oral therapy for 10 years or intravenous bisphosphonate for 6 years or switch to new therapy

- ✓ Persistent osteoporosis at the hip
- ✓ Recent fracture(s) during therapy
- ✓ Multiple prevalent spine fractures

ASBMR TASK FORCE



Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. JBMR 2016 52

52

Imminent Fracture Risk: Why it is Important



- Patient with a recent fracture and/or very low BMD (T-score <-3.0) are at elevated risk of fractures *one or two years after fracture*
- It is important to treat patients promptly after a fracture to reduce fracture risk
- Some osteoporosis medications reduce fracture in the first year (e.g., zoledronic acid, denosumab, romosozumab)
- Speed of effect onset of osteoporosis medications should be considered in relation to a patient's imminent fracture risk



53

53

Pharmacologic Treatment Considerations Reviewed in the Clinician's Guide 2022

- Improving patient adherence with prescribed treatment; assess compliance and persistence at least yearly
- **Treat-to-target** management recommendations
- **Endocrine Society's treatment algorithms** on the management of postmenopausal osteoporosis according to fracture risk
- Antifracture treatment in **men with osteoporosis**
- Antifracture treatment in patients treated with **glucocorticoids**
- Evidence for antifracture benefits for **older-old adults**



54

54

Rehabilitation Following Fragility Fractures

- ✓ Hip
- ✓ Spine
- ✓ Wrist



55

Pain Management Strategies and Interventions for Osteoporotic Fractures

Pain Management Measure

Acetaminophen	Cognitive Behavioral Therapy
Acupuncture	Complementary Therapies
Antidepressants (Amitriptyline, Duloxetine)	Electric stimulation
Anti-inflammatories (NSAIDs)	Ice and heat
Antiepileptics	Massage
Antispasmodics	Nerve root block injection
Aspirin	Opioid Use
Bed rest	Topical pain relievers (Capsaicin, Lidocaine)
Bracing and spinal orthoses	Vertebroplasty/kyphoplasty
Calcitonin salmon	




LeBlond AS, Grossman SJ, Hoogwerf BJ, et al. *Osteo* 11: 2018
 Parkman T, et al. *J Pain Res* 2018
 Campbell SM, et al. *Drugs* 2012
 Lanza U, et al. *Drugs* 2005
 Finerman NG, *NSAID* 2018

56


56




57



58



59



60

Thank You!

